29 Nov - 15 Dec 2021Warrent redemption

The company develops patented technologies for the release of already approved or clinically validated drugs based on pegylation to improve the properties of biological drugs. Peglyceration has long been used to modify biological drugs. Normally, drugs are pegylated in such a way that the PEG molecule and the drug are permanently linked. This can lead to disadvantages, for example reduced effect in that the PEG molecule can block the binding of the drug to its target molecule (receptor). To avoid this, QuiaPEG has developed a technology that enables a gradual release of the drug, which retains the benefits of peglyceration while maintaining the full effect of the drug.

Read more on the company's website

---

The offer in summary